Accent Therapeutics Appoints Oncology Drug Development Veteran Julie Hambleton to its Board of Directors

Sept. 25, 2020 11:00 UTC

 

 
 

LEXINGTON, Mass.--(BUSINESS WIRE)-- Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today the appointment of Julie Hambleton, M.D., to its board of directors. Dr. Hambleton brings extensive clinical oncology drug development and regulatory expertise gained in leadership roles within both the biotechnology and pharmaceutical industries.

“We are delighted to welcome Julie to the Accent Board of Directors,” said Shakti Narayan, Ph.D., J.D., Chief Executive Officer of Accent. “Her insight and experience will be invaluable as we continue to advance our pipeline of novel therapies targeting RNA-modifying proteins.”

“Accent is developing an exciting pipeline of targeted therapies in this novel area of biology,” said Dr. Hambleton. “I’m thrilled to be working with the board of directors and the Accent team to deliver life-changing therapies to patients.”

Dr. Hambleton is a senior biotechnology executive with more than 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs) and Special Protocol Assessments (SPAs). Dr. Hambleton currently serves as interim Chief Executive Officer at Arch Oncology. Previously, she served as Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences, an oncology medicine company, until April 2020. Prior to her role at IDEAYA, she held the positions of Vice President, Head of U.S. Medical at Bristol-Myers Squibb, where she oversaw Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios; Executive Vice President and Chief Medical Officer at Five Prime Therapeutics; and Vice President, Clinical Development, at Clovis Oncology.

Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin®. She also serves on the boards of directors of IGM Biosciences, Inc. and SpringWorks Therapeutics, Inc., both publicly traded biotechnology companies, as well as Arch Oncology, a privately-held biotechnology company. Dr. Hambleton completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and her M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

About Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of RNA modification. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, the Company aims to translate extraordinary science into life-changing therapies for patients. For more information, please visit www.accenttx.com.

Contacts

Madelyn Parks
Spectrum Science Communications
mparks@spectrumscience.com
(312.635.6286)

 
 

Source: Accent Therapeutics

Back to news